Frontlight ResearchEarly access
CompletedPhase 2
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Albuquerque, Conroe, and Houston, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 35 people, planned
- Started
- 8 Aug 2016
- Ended
- 19 Apr 2024
- Type of study
- Interventional
- Treatments tested
- Frameless Fractionated Stereotactic Radiation Therapy
- Record updated
- 23 April 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- All patients with 1-4 metastatic brain lesions who are considered eligible for single-fraction, frame-based SRS, who are unable or unwilling to undergo frame-based SRS
- One to 4 untreated metastatic brain lesions
- Each brain lesion must be less than or equal to 5 cm in diameter and not an optimal surgical candidate
- Patient must be able have a magnetic resonance imaging (MRI) of the brain for treatment planning
- Histologic confirmation of malignancy
- For patients of childbearing potential, non-pregnant state, confirmed by negative serum or urine beta-human chorionic gonadotropin (HCG) within (7) days of planned radiation treatment
- Glomerular filtration rate (GFR) adequate for intravenous (IV) contrast delivery for imaging
- No concurrent chemotherapy
- Patient may have had prior therapy for brain metastasis, including radiosurgery and surgical resection at the discretion of the treating physician however only new untreated lesions will be followed on protocol
Who cannot take part
- Patients willing to be treated with frame-based gamma knife SRS at MD Anderson main campus or MD Anderson at the Woodlands
- Primary small cell lung cancer, myeloma, lymphoma, leukemia, or other histologies not optimally treated with SRS
- Patients currently receiving chemotherapy/biologic/immunotherapy as these need to be held during FFSRT
- Prior whole brain radiotherapy or conventional external beam radiotherapy
- Positive pregnant status confirmed by serum or urine pregnancy test
- Five or more metastatic brain lesions
- Brain lesion(s) greater than 5 cm in diameter
- Lesion(s) involving the brainstem, optic chiasm or optic nerve(s)
- Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
- Patient unable to have an MRI of the brain
Where in United States
- Presbyterian HospitalAlbuquerque, United States
- MD Anderson in The WoodlandsConroe, United States
- M D Anderson Cancer CenterHouston, United States
- MD Anderson West HoustonHouston, United States
About the trial
What the trial wants to find out
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions while sparing normal tissues.
The group in the trial
- Treatment (FFSRT)Treatment being tested
Patients undergo FFSRT daily over 30 minutes for 3-5 days.
Treatment: Frameless Fractionated Stereotactic Radiation Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study of the Efficacy, Safety, and Cost of Frameless Fractionated Stereotactic Radiation for Parenchymal Brain Metastases
- Record updated
- 23 April 2024